Saenz‐de‐Viteri M, Recalde S, Fernandez‐Robredo P, et al. - Using data collected from the In-Eye study, a prospective 12-month, three-armed, multicenter (31 sites in Spain), randomized phase IV clinical trial, researchers performed this post hoc analysis to evaluate the impact of fluid status at baseline (BL) and at the end of the loading phase (LP) of three different ranibizumab regimens: treat‐and‐extend (T&E), fixed bimonthly (FBM) injections and pro re nata (PRN), in patients with neovascular age‐related macular degeneration (nAMD). Participants were randomized 1:1:1 to the three study arms and were treated accordingly. SRF patients had better visual outcomes than IRF patients at LP. Although SRF is associated with good visual and anatomical outcomes, IRF is linked to poorer outcomes in patients with nAMD; the findings suggest that patients with IRF have better outcomes when individualized treatment regimens are used (PRN or T&E) rather than an FBM regimen.